These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 16231968)

  • 1. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
    Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
    Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.
    Yasui-Furukori N; Saito M; Uno T; Takahata T; Sugawara K; Tateishi T
    J Clin Pharmacol; 2004 Nov; 44(11):1223-9. PubMed ID: 15496639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
    Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
    Eur J Clin Pharmacol; 2004 Nov; 60(9):623-8. PubMed ID: 15448955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
    Uno T; Shimizu M; Yasui-Furukori N; Sugawara K; Tateishi T
    Br J Clin Pharmacol; 2006 Mar; 61(3):309-14. PubMed ID: 16487224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
    Saito M; Yasui-Furukori N; Uno T; Takahata T; Sugawara K; Munakata A; Tateishi T
    Br J Clin Pharmacol; 2005 Mar; 59(3):302-9. PubMed ID: 15752376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19.
    Rost KL; Roots I
    Hepatology; 1996 Jun; 23(6):1491-7. PubMed ID: 8675169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Finasteride 1 mg has no inhibitory effect on omeprazole metabolism in extensive and poor metabolizers for CYP2C19 in Japanese.
    Yasumori T; Narita H; Matsuda T; Takubo T; Ogawa M; Ishii M; Hara K; Ishii Y; Okuyama K; Fujimoto G; Ochiai H; Kano A; Hasegawa S; Sato K; Taniguchi T
    Eur J Clin Pharmacol; 2006 Nov; 62(11):939-46. PubMed ID: 16953457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations.
    Uno T; Niioka T; Hayakari M; Yasui-Furukori N; Sugawara K; Tateishi T
    Eur J Clin Pharmacol; 2007 Feb; 63(2):143-9. PubMed ID: 17203292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
    Sugimoto M; Furuta T; Shirai N; Kajimura M; Hishida A; Sakurai M; Ohashi K; Ishizaki T
    Clin Pharmacol Ther; 2004 Oct; 76(4):290-301. PubMed ID: 15470328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers.
    Yamada S; Shiohira H; Yasui-Furukori N; Tateishi T; Akamine Y; Uno T
    Eur J Clin Pharmacol; 2013 Jul; 69(7):1423-8. PubMed ID: 23435615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.
    Yasui-Furukori N; Takahata T; Nakagami T; Yoshiya G; Inoue Y; Kaneko S; Tateishi T
    Br J Clin Pharmacol; 2004 Apr; 57(4):487-94. PubMed ID: 15025747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.
    Uno T; Sugimoto K; Sugawara K; Tateishi T
    Ther Drug Monit; 2008 Jun; 30(3):276-81. PubMed ID: 18520598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals.
    Isaza C; Henao J; Martínez JH; Sepúlveda Arias JC; Beltrán L
    BMC Clin Pharmacol; 2007 Jul; 7():6. PubMed ID: 17623107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent.
    He N; Huang SL; Zhu RH; Tan ZR; Liu J; Zhu B; Zhou HH
    Xenobiotica; 2003 Feb; 33(2):211-21. PubMed ID: 12623762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omeprazole disposition in children following single-dose administration.
    Kearns GL; Andersson T; James LP; Gaedigk A; Kraynak RA; Abdel-Rahman SM; Ramabadran K; van den Anker JN
    J Clin Pharmacol; 2003 Aug; 43(8):840-8. PubMed ID: 12953341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism.
    Sagar M; Tybring G; Dahl ML; Bertilsson L; Seensalu R
    Gastroenterology; 2000 Sep; 119(3):670-6. PubMed ID: 10982760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping.
    Lawson EB; Wu JC; Baldwin RM; Ingelman-Sundberg M; Rosenborg S; Yim DS; Yin OQ; Capparelli EV; Ma JD
    Eur J Clin Pharmacol; 2012 Apr; 68(4):407-13. PubMed ID: 22009190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes.
    Hu YR; Qiao HL; Kan QC
    Acta Pharmacol Sin; 2004 Aug; 25(8):986-90. PubMed ID: 15301728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of the cytochrome P450 2C19 genetic polymorphism.
    Desta Z; Zhao X; Shin JG; Flockhart DA
    Clin Pharmacokinet; 2002; 41(12):913-58. PubMed ID: 12222994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes.
    Roh HK; Kim PS; Lee DH; Tybring G; Sagar M; Park CS; Seensalu R; Bertilsson L
    Basic Clin Pharmacol Toxicol; 2004 Sep; 95(3):112-9. PubMed ID: 15447734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.